Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859357 | 0.88 | ELANE (0.34) | ELANEAAK1CHRM2CHRM1CHRM3 | |
| SCHEMBL896532 | 0.85 | DPP4 (0.49) | DPP4 | |
| SCHEMBL895743 | 0.83 | ELANE (0.32) | ELANEDPP4AAK1CHRM2CHRM1 | |
| SCHEMBL10026720 | 0.81 | CHRM2 (0.39) | ELANEAAK1CHRM2CHRM1CHRM3 | |
| SCHEMBL895624 | 0.81 | CHRM2 (0.39) | ELANEAAK1CHRM2CHRM1CHRM3 | |
| SCHEMBL894936 | 0.80 | CHRM2 (0.38) | ELANEAAK1CHRM2CHRM1CHRM3 | |
| SCHEMBL10026719 | 0.80 | CHRM2 (0.38) | ELANEAAK1CHRM2CHRM1CHRM3 | |
| SCHEMBL3738734 | 0.79 | BCL2 (0.38) | AAK1 | |
| SCHEMBL3755810 | 0.79 | PREP (0.34) | ELANEAAK1PRSS1PRSS2PRSS3 | |
| SCHEMBL11965227 | 0.77 | CHRM2 (0.41) | ELANEAAK1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748457-B2 | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors | LUPIN LIMITED (IN) | 2014-06-10 | — | — | US | disclosed |
| US-8748457-B2 | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors | LUPIN LIMITED (IN) | 2014-06-10 | — | — | US | disclosed |
| US-8748457-B2 | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors | LUPIN LIMITED (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120082635-A1 | 2-AMINO-2- [8-(DIMETHYL CARBAMOYL)- 8-AZA- BICYCLO [3.2.1] OCT-3-YL]-EXO- ETHANOYL DERIVATIVES AS POTENT DPP-IV INHIBITORS | LUPIN LIMITED (IN) | 2012-04-05 | — | — | US | disclosed |
| US-20120082635-A1 | 2-AMINO-2- [8-(DIMETHYL CARBAMOYL)- 8-AZA- BICYCLO [3.2.1] OCT-3-YL]-EXO- ETHANOYL DERIVATIVES AS POTENT DPP-IV INHIBITORS | LUPIN LIMITED (IN) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082635-A1 | 2-AMINO-2- [8-(DIMETHYL CARBAMOYL)- 8-AZA- BICYCLO [3.2.1] OCT-3-YL]-EXO- ETHANOYL DERIVATIVES AS POTENT DPP-IV INHIBITORS | DPP7, DPP4, DPP8 | ELANE 1201/4885DPP4 2/4885AAK1 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.